Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CNS Pharmaceuticals Inc CNSP

Healthcare
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for... see more

Recent & Breaking News (NDAQ:CNSP)

CNS Pharmaceuticals to Discuss Phase 2 Clinical Trial Design to be Submitted for FDA Review in Webcast at 4:30 PM ET Today

PR Newswire November 12, 2020

CNS Pharmaceuticals Announces Adaptive Trial Design For Berubicin Phase 2 Clinical Trial To Be Submitted for FDA Review

PR Newswire November 9, 2020

CNS Pharmaceuticals Completes Manufacturing of Berubicin for Phase 2 Clinical Trial

PR Newswire October 29, 2020

CNS Pharmaceuticals Completes U.S. Manufacturing of Berubicin for Phase 2 Clinical Trial

PR Newswire October 20, 2020

CNS Pharmaceuticals Highlights New Balancing Act Segment on Glioblastoma Airing on Lifetime TV

PR Newswire October 12, 2020

CNS Pharmaceuticals Begins Manufacturing of Berubicin in Europe

PR Newswire October 9, 2020

CNS Pharmaceuticals Achieves Critical Manufacturing Milestone

PR Newswire October 1, 2020

CNS Pharmaceuticals and Image Analysis Group Partner to Further the Development of Berubicin

GlobeNewswire September 24, 2020

CNS Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

PR Newswire September 17, 2020

CNS Pharmaceuticals to Present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference

PR Newswire September 11, 2020

CNS Pharmaceuticals Announces US Drug Manufacturing Milestones

GlobeNewswire September 3, 2020

CNS Pharmaceuticals Announces Appointment of Dr. Patrick Wen, Director of Center for Neuro-Oncology at Dana-Farber Cancer Institute, to Science Advisory Board

PR Newswire August 27, 2020

CNS Provides FDA Update on IND Filing

PR Newswire August 25, 2020

CNS Pharmaceuticals Engages CRO For Phase 2 Berubicin Clinical Trials

PR Newswire August 20, 2020

CNS Pharmaceuticals to Provide Second Quarter 2020 Business Update on Thursday, August 13, 2020

PR Newswire August 11, 2020

CNS Pharmaceuticals Recognizes Glioblastoma Awareness Day

PR Newswire July 22, 2020

CNS Pharmaceuticals Completes Drug Product Manufacturing Strategy for Berubicin

PR Newswire July 15, 2020

CNS Pharmaceuticals Completes Active Ingredient Shipments to Manufacturers

PR Newswire July 8, 2020

CNS Pharmaceuticals Engages Berry Consultants to Advise Phase 2 Trial Design

PR Newswire June 30, 2020

Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing

GlobeNewswire June 29, 2020